PCI Biotech Holding ASA (OSL:PCIB)
Norway
· Delayed Price · Currency is NOK 0.2520
-0.0080 (-3.08%)
At close: Dec 5, 2025
PCI Biotech Holding ASA Revenue
PCI Biotech Holding ASA had revenue of 1.38M NOK in the half year ending June 30, 2025, with 230.70% growth. This brings the company's revenue in the last twelve months to 4.69M, down -21.85% year-over-year. In the year 2024, PCI Biotech Holding ASA had annual revenue of 6.74M with 125.25% growth.
Revenue (ttm)
4.69M
Revenue Growth
-21.85%
P/S Ratio
2.01
Revenue / Employee
937.60K
Employees
5
Market Cap
9.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.74M | 3.75M | 125.25% |
| Dec 31, 2023 | 2.99M | -1.76M | -37.05% |
| Dec 31, 2022 | 4.75M | -1.52M | -24.28% |
| Dec 31, 2021 | 6.27M | -1.10M | -14.86% |
| Dec 31, 2020 | 7.37M | -2.02M | -21.55% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 662.18M |
| Nordhealth AS | 590.33M |
| Photocure ASA | 537.59M |
| ArcticZymes Technologies ASA | 109.99M |
| Omda AS | 476.29M |
| Vistin Pharma ASA | 455.25M |
| Gentian Diagnostics ASA | 172.52M |
| Nykode Therapeutics AS | 73.37M |